{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000207","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.237919+00:00","generated_at":"2026-05-16T13:20:35.358645+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Emergent BioSolutions receives FDA approval for raxibacumab manufacturing at Winnipeg site","bullets":["FDA approved sBLA for Winnipeg as drug product manufacturing and testing site for raxibacumab.","Raxibacumab is a monoclonal antibody for treatment and prophylaxis of inhalational anthrax.","Approval supports multi-year turnaround strategy to consolidate manufacturing in Winnipeg and Lansing.","Winnipeg facility has over 45 years experience in commercial therapeutics manufacturing.","CEO Joe Papa says this regulatory action advances flexible, streamlined manufacturing network."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000207","json":"https://secwatch.observer/filing/0001367644-25-000207.json","markdown":"https://secwatch.observer/filing/0001367644-25-000207.md","text":"https://secwatch.observer/filing/0001367644-25-000207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/0001367644-25-000207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000207/ebs-20251212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:20:35.358645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}